JP2022513075A - タウオパチーの処置のための、タウペプチド抗原およびそれに結合する抗体 - Google Patents

タウオパチーの処置のための、タウペプチド抗原およびそれに結合する抗体 Download PDF

Info

Publication number
JP2022513075A
JP2022513075A JP2021527115A JP2021527115A JP2022513075A JP 2022513075 A JP2022513075 A JP 2022513075A JP 2021527115 A JP2021527115 A JP 2021527115A JP 2021527115 A JP2021527115 A JP 2021527115A JP 2022513075 A JP2022513075 A JP 2022513075A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
tau
subject
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021527115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513075A5 (enExample
Inventor
マーク アイ． ダイアモンド
ケネス ドロンボスキー
ダイル チェン
ヴィクター マノン
シャオフア リュウ
ハミド ミルザイ
ジャイム ヴァケール－アリシア
ヒルダ ミルバハ
ルーカス ジョーチミアク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022513075A publication Critical patent/JP2022513075A/ja
Publication of JP2022513075A5 publication Critical patent/JP2022513075A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
JP2021527115A 2018-11-19 2019-11-18 タウオパチーの処置のための、タウペプチド抗原およびそれに結合する抗体 Pending JP2022513075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769281P 2018-11-19 2018-11-19
US62/769,281 2018-11-19
PCT/US2019/061928 WO2020106598A1 (en) 2018-11-19 2019-11-18 Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies

Publications (2)

Publication Number Publication Date
JP2022513075A true JP2022513075A (ja) 2022-02-07
JP2022513075A5 JP2022513075A5 (enExample) 2023-01-10

Family

ID=70773408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527115A Pending JP2022513075A (ja) 2018-11-19 2019-11-18 タウオパチーの処置のための、タウペプチド抗原およびそれに結合する抗体

Country Status (5)

Country Link
US (1) US20220273779A1 (enExample)
EP (1) EP3883602A4 (enExample)
JP (1) JP2022513075A (enExample)
CN (1) CN113490505A (enExample)
WO (1) WO2020106598A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CA3079236A1 (en) * 2017-10-27 2019-05-02 United Neuroscience Tau peptide immunogen constructs
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
CN116549632B (zh) * 2023-03-28 2024-09-10 中国人民解放军军事科学院军事医学研究院 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000037188A (ja) * 1991-12-06 2000-02-08 Max Planck G Zur Foerderung Wissenschaft Ev アルツハイマー病の診断および治療用の新規な手段
JP2014530597A (ja) * 2011-09-19 2014-11-20 アクソン ニューロサイエンス エスエー アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断
US20180002414A1 (en) * 2006-03-29 2018-01-04 New York University Immunotherapy for Clearing Pathological Tau Conformers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000037188A (ja) * 1991-12-06 2000-02-08 Max Planck G Zur Foerderung Wissenschaft Ev アルツハイマー病の診断および治療用の新規な手段
US20180002414A1 (en) * 2006-03-29 2018-01-04 New York University Immunotherapy for Clearing Pathological Tau Conformers
JP2014530597A (ja) * 2011-09-19 2014-11-20 アクソン ニューロサイエンス エスエー アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法

Also Published As

Publication number Publication date
EP3883602A1 (en) 2021-09-29
WO2020106598A1 (en) 2020-05-28
EP3883602A4 (en) 2023-04-12
US20220273779A1 (en) 2022-09-01
CN113490505A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
JP2022513075A (ja) タウオパチーの処置のための、タウペプチド抗原およびそれに結合する抗体
US11739140B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP7029415B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
JP6641305B2 (ja) 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片
CN110267985B (zh) 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
JP2026032030A (ja) ＲＧＭａ結合タンパク質及びその使用
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
US8642041B2 (en) Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation
JP7618240B2 (ja) 脳神経系疾患の予防または治療用組成物
CN111263820A (zh) 抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
JP2023554382A (ja) タウ結合化合物
TWI734279B (zh) 抗α-突觸核蛋白抗體及其用途
WO2023206609A1 (zh) 针对p-tau 217的抗体及其用途
WO2022132641A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
JP2021119781A (ja) 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片
WO2026039731A1 (en) Antibody genetics of radiologically isolated syndrome
US11397188B2 (en) Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
WO2026019699A1 (en) Engineered cells to detect and respond to tau
CN118510800A (zh) 靶向白细胞介素-34的化合物和方法
HK40115197A (zh) 抗序列相似家族19成员a5抗体用於治疗和诊断情绪障碍的用途
CN118475609A (zh) 靶向白细胞介素-34的化合物和方法
EP4179333A1 (en) Use of gdf11 to diagnose and treat anxiety and depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240516